Sino Bio­pharm, Or­biMed back Mer­ck-part­nered Ake­so­bio's bet on made-in-Chi­na an­ti­bod­ies

In the lat­est boost for Chi­na’s flour­ish­ing an­ti­body R&D scene, Mer­ck-part­nered Ake­so­bio has bagged $150 mil­lion in Se­ries D cash to push a slate of drugs tar­get­ing can­cer, au­toim­mune dis­or­ders and even hy­per­lipi­demia.

Ake­so­bio’s lead drugs hit some well-es­tab­lished tar­gets like PD-1, CT­LA-4, IL12 and IL23. But its suite of in-house tech­nolo­gies — in­clud­ing the “Tetra­body” bis­pe­cif­ic plat­form — sets it apart, ac­cord­ing to the biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER